Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Blood group genotyping of blood donors: validation of a highly accurate routine method

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Oral iron supplementation is not associated with short-term risk of infections: results from the Danish Blood Donor Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Frequent blood donation and offspring scholastic attainment: an assessment of long-term consequences of prenatal iron deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Frequent blood donation and offspring birth weight-a next-generation association?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Endothelial glycocalyx shedding in patients with burns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Storage time of red blood cells among ICU patients with septic shock

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Use of red blood cells in Danish intensive care units: A population-based register study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Platelet increment is not associated with endothelial damage in haematological patients: a prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: This trial evaluated the efficacy and safety of intravenous (IV) iron isomaltoside (Monofer) in comparison with placebo in first-time female blood donors.

STUDY DESIGN AND METHODS: The trial was a prospective, double blind, placebo-controlled, randomized, comparative, single-center trial of 85 first-time female blood donors. The subjects were randomly assigned 1:1 to either 1000 mg IV iron isomaltoside infusion or placebo. The primary endpoint of the trial was change in hemoglobin (Hb) from baseline to right before the third blood donation.

RESULTS: The increase in Hb was significantly higher for iron isomaltoside compared with placebo right before both the second blood donation (p = 0.0327) and the third blood donation (primary endpoint, p < 0.0001). Improvements in other iron-related variables (plasma iron, plasma ferritin, transferrin saturation, and reticulocyte count) in favor of iron isomaltoside were also observed. The trial was not powered on patient-reported outcomes. However, improvements in iron stores and Hb levels after iron isomaltoside administration were supported by the fact that several of the fatigue symptoms scores showed numerical differences in favor of iron isomaltoside. There were no differences in side effects between the groups.

CONCLUSION: In iron-deficient female blood donors a single IV iron isomaltoside administration resulted in an improvement in Hb concentration and iron stores and demonstrated a favorable safety profile comparable to placebo.

OriginalsprogEngelsk
TidsskriftTransfusion
Vol/bind58
Udgave nummer4
Sider (fra-til)974-981
Antal sider8
ISSN0041-1132
DOI
StatusUdgivet - apr. 2018

ID: 55409827